Alpine Immune Sciences Presents Promising Translational Data on Povetacicept and Acazicolcept for the Treatment of Lupus and Glomerulonephritis
Alpine Immune Sciences, a leading clinical-stage immunotherapy company, recently presented new translational data on two of their innovative treatments for autoimmune and inflammatory diseases at prestigious medical conferences. The presentations shed light on the potential of povetacicept (ALPN-303) and acazicolcept (ALPN-101) in the treatment of systemic lupus erythematosus (SLE) and autoimmune glomerulonephritis.
At the SLEuro 14th European Lupus Meeting in Bruges, Belgium, Alpine Immune Sciences unveiled compelling translational data on povetacicept. The data demonstrated that the gene expressions related to BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) were significantly increased in myeloid and B cells in patients with systemic lupus erythematosus. This finding suggests that povetacicept may hold promise as a potential therapeutic option for this debilitating autoimmune disease.
Furthermore, the company also previously presented translational data for acazicolcept in systemic lupus erythematosus at the American College of Rheumatology Convergence 2023 in Seattle. The data highlighted the significant increase in gene expressions related to acazicolcept targets, indicating its potential efficacy in treating SLE.
In another breakthrough, Alpine Immune Sciences presented the first clinical data of povetacicept in autoimmune glomerulonephritis at the American Society of Nephrology (ASN) Kidney Week in Philadelphia. Glomerulonephritis is a condition that causes inflammation in the tiny filters of the kidneys, leading to kidney damage. The initial clinical findings suggest that povetacicept could be a promising treatment option for this condition, offering hope to patients suffering from autoimmune kidney diseases.
These positive results from translational studies and early clinical data indicate the potential of povetacicept and acazicolcept in addressing the unmet needs of patients with autoimmune and inflammatory diseases. Alpine Immune Sciences is pioneering the development of innovative immunotherapy treatments to improve the lives of millions of individuals battling these conditions.
Comments